EMA Refused: Genasense (oblimersen) — Genta Development Ltd. c/o Ross Craig

View source ↗

Summary

The EMA refused approval for Genasense (oblimersen) for melanoma, indicating a negative outcome in the regulatory decision.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Genasense (oblimersen)

Snippet

Status: Refused. Therapeutic area: Melanoma. MAH: Genta Development Ltd. c/o Ross Craig. Decision date: 31/12/2009